RPL17 and neoplasm: Interaction between PD-1 and its ligand (PD-L1) facilitates negative regulation of effector immune cells by inducing the death of cytotoxic lymphocytes in the tumor microenvironment and enhancing regulatory T-lymphocyte activity.